Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20863032 | 0.82 | CASP2 (0.45) | MTNR1AMTNR1B | |
| SCHEMBL14930642 | 0.81 | — | — | |
| SCHEMBL8964 | 0.80 | MEN1 (0.50) | MEN1KMT2AMTNR1AMTNR1BCYP2C9 | |
| SCHEMBL23341003 | 0.79 | CYP1A2 (0.32) | CYP1A2RECQL | |
| SCHEMBL12742134 | 0.79 | HPGD (0.42) | MEN1KMT2ACYP2C9CYP1A2SMN1; SMN2 | |
| SCHEMBL24245534 | 0.79 | MEN1 (0.40) | MEN1KMT2AMTNR1AMTNR1BCYP2C9 | |
| SCHEMBL12947998 | 0.78 | MEN1 (0.48) | MEN1KMT2AMTNR1AMTNR1BCYP2C9 | |
| SCHEMBL14302929 | 0.76 | MEN1 (0.46) | MEN1KMT2AMTNR1AMTNR1BCYP2C9 | |
| SCHEMBL5940256 | 0.76 | MEN1 (0.46) | MEN1KMT2AMTNR1AMTNR1BCYP2C9 | |
| SCHEMBL12847744 | 0.76 | MEN1 (0.46) | MEN1KMT2AMTNR1AMTNR1BCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9669027-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9212168-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | MEN1 3387/4885KMT2A 3141/4885MTNR1A 4459/4885 |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | MEN1 3387/4885KMT2A 3141/4885MTNR1A 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.